Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sézary syndrome

The PD-1 inhibitor pembrolizumab is effective in treating Sézary syndrome, a leukemic variant of cutaneous T-cell lymphoma. Our purpose was to investigate the effects of pembrolizumab on healthy and malignant T cells in Sézary syndrome and to discover characteristics that predict pembrolizumab respo...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Tianying, Duran, George E., Kwang, Alexa C., Ramchurren, Nirasha, Fling, Steven P., Kim, Youn H., Khodadoust, Michael S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9423847/
https://www.ncbi.nlm.nih.gov/pubmed/36046812
http://dx.doi.org/10.1080/2162402X.2022.2115197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9423847/
https://www.ncbi.nlm.nih.gov/pubmed/36046812
http://dx.doi.org/10.1080/2162402X.2022.2115197

Ejemplares similares